Investment and M&A transaction comps
Healthcare Investment & M&A Transaction Comps
Healthcare services, healthcare IT, medtech, diagnostics, life sciences tools and related healthcare transactions. Pure biotech rows are tracked separately where normal revenue multiples are less meaningful.
50
Reviewed transactions
19
With price data
4.6x
Median EV or valuation / revenue
15.1x
Median EV or valuation / EBITDA
| Year | Transactions | Priced | Median EV or valuation / revenue | Median EV or valuation / EBITDA |
|---|---|---|---|---|
| 2026 | 32 | 8 | 6.0x | - |
| 2025 | 3 | 0 | - | - |
| 2022 | 3 | 1 | 4.9x | 17.1x |
| 2021 | 3 | 2 | - | 11.9x |
Sortable transaction comps
Healthcare transaction table
Rows with reported value
6 / 25
Acquisition EV, USD
USD 7.9B
Investment EV, USD
-
Median EV / revenue
6.0x
Select up to 12 rows across filters and pages, then share or export the set.
Selected comparison set
Saved in this browser only. Nothing is written to FundComb data.
Choose transactions from the table to build a quick comparison set.
25 shown of 50 matching transactions. Click any transaction row for more detail.
Values are 100% enterprise values. Multiples divide EV by full-company revenue or EBITDA. Reported prices are assumed to be EV; explicit partial-stake prices are grossed up as estimates. Amounts paid are tracked separately.
| Select for comparison | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Sohar Health Control | 2026-10-14 | Zocdoc | Undisclosed | Undisclosed | - | - | New York, USA | Confirmed 2 sources | ||
| Sofie Biosciences Control | 2026-10-05 | GE HealthCare | USD 945M Enterprise Value | 945 | - | - | United States | Confirmed 3 sources | ||
| IMATS Control | 2026-09-22 | Command Medical | Undisclosed | Undisclosed | - | - | - | Confirmed 2 sources | ||
| ITM Isotope Technologies Munich SE Control (100%) | 2026-09-20 | Telix Pharmaceuticals Limited | USD 1.6B Enterprise Value | 1,650 | 6.0x | - | Germany | Confirmed 3 sources | ||
| Vyne Medical Control | 2026-09-16 | MRO | Undisclosed | Undisclosed | - | - | United States | Confirmed 2 sources | ||
| AtaiBeckley Control | 2026-09-11 | Eli Lilly and Company | USD 2.8B Enterprise Value | 2,800 | - | - | - | Confirmed 2 sources | ||
| 2026-08-26 | CoreHealth Technologies | Undisclosed Undisclosed | Undisclosed | - | - | - | Confirmed 2 sources | |||
| Dersimelagon rights Control | 2026-08-18 | LEO Pharma | USD 435M Consideration | 435 | - | - | Denmark / Japan | Confirmed 3 sources | ||
| Circulate Health Control | 2026-08-12 | Viome | Undisclosed | Undisclosed | - | - | United States | Confirmed 2 sources | ||
| E-Pharma Trento Control (100%) | 2026-08-07 | Wise Equity | Undisclosed | Undisclosed | - | - | Italy | Confirmed 1 source | ||
| Texas MedClinic Control | 2026-08 | HCA Healthcare | Undisclosed | Undisclosed | - | - | Texas, United States | Confirmed 1 source | ||
| BIO-CAT Enzymes & Microbials Control | 2026-07-31 | Lallemand Inc. | Undisclosed | Undisclosed | - | - | United States | Confirmed 1 source | ||
| Avanos Medical, Inc. Control | 2026-07-27 | American Industrial Partners | Undisclosed | Undisclosed | - | - | United States | Confirmed 1 source | ||
| 2026-07-20 | Eurofins | Undisclosed | Undisclosed | - | - | North America | Confirmed 1 source | |||
| 2026-07-13 | Servier | Undisclosed | Undisclosed | - | - | - | Confirmed 2 sources | |||
| Spire Healthcare portfolio Control | 2026-07-08 | Funds managed by Blue Owl Capital | Undisclosed | Undisclosed | - | - | - | Confirmed 1 source | ||
| MatrixCare Control | 2026-07-07 | Frazier Healthcare Partners | Undisclosed | Undisclosed | - | - | United States | Confirmed 1 source | ||
| Myricx Bio Control | 2026-07-06 | Novartis | USD 1.5B Consideration | 1,500 | - | - | United Kingdom | Confirmed 2 sources | ||
| 2026-07-06 | Altaris LLC | USD 600M Consideration | 600 | - | - | - | Confirmed 1 source | |||
| Bio-Techne Control | 2026-06-25 | Merck KGaA, Darmstadt, Germany | Undisclosed | Undisclosed | - | - | United States / Germany | Confirmed 1 source | ||
| 4E Therapeutics Control | 2026-06-16 | Eli Lilly and Company | Undisclosed | Undisclosed | - | - | - | Confirmed 1 source | ||
| 2026-05-27 | HCA Healthcare | Undisclosed | Undisclosed | - | - | - | Confirmed 2 sources | |||
| Tubulis Control | 2026-05-21 | Gilead Sciences | Undisclosed | Undisclosed | - | - | Germany | Confirmed 1 source | ||
| SPR Therapeutics Control | 2026-05-20 | Medtronic | Undisclosed Undisclosed | Undisclosed | - | - | - | Confirmed 1 source | ||
| Cross Country Healthcare Control | 2026-05 | Knox Lane | Undisclosed | Undisclosed | - | - | - | Confirmed 1 source |
FundComb transaction comps are informational only. Prices are shown as estimated enterprise value where available, with USD used as the default sorting currency; revenue and EBITDA multiples are shown where available. Values may be estimated, rumored, incomplete or derived from public information and should not be relied upon as financial, investment or valuation advice.